Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2017 | Next steps in VTE treatment: will oral edoxoban replace the current standard of care?

Harry Buller • 10 Dec 2017
ASH 2017
General Edoxaban
HOKUSAI-VTE

There was exciting news at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA, with data from the Hokusai venous thromboembolism (VTE)-Cancer Study (NCT02073682) presented as a late-breaking abstract. Here, Harry Buller, MD, PhD, of the Academic Medical Centre, Amsterdam, Netherlands, discusses whether oral edoxoban could become the new standard of care for cancer-associated VTE. Prof. Buller also shares his predictions on the future of VTE treatment following the success of the Hokusai VTE-Cancer Study.

More from Harry Buller

3:55
The Hokusai VTE-Cancer Study: objectives and design
Harry Buller • 10 Dec 2017
2:27
The Hokusai VTE-Cancer Study: the importance of improving VTE treatment
Harry Buller • 10 Dec 2017

Related Videos

4:33
The EBMT Patient Advocacy Committee: Patient, Family and Donor Day at EBMT 2024
Natacha Bolaños • 16 Apr 2024
2:55
Distinguishing late-onset neutropenia from classical primary neutropenia
Carlo Dufour • 15 Apr 2024
2:39
The MAGIC algorithm probability to predict outcomes of GvHD in the GI tract
James Ferrara • 16 Apr 2024
2:25
The EBMT Trainee Committee: in-person trainee day at EBMT 2024 and upcoming initiatives
Claire Horgan • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals